This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Genomic Health To Present At Two Upcoming Investor Conferences

REDWOOD CITY, Calif., May 28, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that members of its management team will present at the following conferences in June:

  • Jefferies 2013 Global Healthcare Conference on Monday, June 3 at 4:30 p.m. Eastern Time (ET) in New York City; and
  • Goldman Sachs 34th Annual Global Healthcare Conference on Tuesday, June 11 at 2:00 p.m. Pacific Time (PT) in Rancho Palos Verdes, California.

(Logo: http://photos.prnewswire.com/prnh/20130425/SF01493LOGO)

To access the live and subsequently archived webcast of the presentations, go to the  Investor Relations section of the company's website at http://investor.genomichealth.com.  Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.  An archived replay will be available for three months beginning 24 hours after the live presentation.

About Genomic Health Genomic Health, Inc. (NASDAQ:  GHDX) is a global healthcare company that provides actionable genomic information to personalize cancer treatment decisions.  The company's lead product, the  Oncotype DX® breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive  breast cancer and has been shown to predict the likelihood of recurrence in  ductal carcinoma in situ (DCIS).  In addition to this widely adopted test,  Genomic Health provides the  Oncotype DX colon cancer test, the first multi-gene expression test developed for the assessment of risk of recurrence in patients with  stage II and stage III disease and the Oncotype DX prostate cancer test, which predicts disease aggressiveness in men with low risk disease.  As of March 31, 2013, more than 19,000 physicians in over 70 countries had ordered more than 350,000 Oncotype DX tests.  Genomic Health has a robust  pipeline focused on developing tests to optimize the treatment of renal cell cancers, as well as additional treatment decisions in breast, colon and prostate cancers.  The company is based in  Redwood City, California with European headquarters in Geneva, Switzerland. 

For more information, please visit www.GenomicHealth.com and follow the company on Twitter:  @GenomicHealth.  To learn more about  Oncotype DX tests visit:  www.OncotypeDX.com and  www.mybreastcancertreatment.org and  www.myprostatecancertreatment.org.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the attributes and focus of the company's product pipeline; the applicability of clinical study results to actual outcomes; the potential economic benefits associated with the company's tests; the ability of the company to develop additional tests in the future; the demand for the company's tests; the ability of any potential tests the company may develop to optimize cancer treatment and the Company's ability to launch new tests in new markets and expand internationally. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of the company's tests; the results of clinical studies; the applicability of clinical study results to actual outcomes; our ability to develop and commercialize new tests; unanticipated costs or delays in research and development efforts; our ability to obtain capital when needed and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2013. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.   

SOURCE Genomic Health, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs